Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines

Anti-Cancer Drugs

Volumn 10, Issue 1, 1999, Pages 119-127

  Fujita, Manabu ^a   Tsuchida, Tetsuo ^a   Higashino, Kazuya ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Anti cancer drugs; Apoptosis; Lung cancer cell lines; Vesnarinone

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; GEMCITABINE; PIPERANOMETOZINE; QUINOLONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG RESISTANCE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0033061023     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199901000-00015     Document Type: Article

References (31)

1. Inoue M, Kim B-H, Hori M, et al. Oral OPC-8212 for the treatment of congestive heart failure: hemodynamic improvement and increased exercise capacity. Heart Vessels 1986; 2: 166-71.
2. Hori M, Inoue M, Tamai J, et al. Beneficial effect of OPC-8212 (3,4-dihydro-6[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone) on myocardial oxygen consumption in dogs with ischemic heart failure. Jpn Circ J 1986; 50: 659-66.
3. Asanoi H, Sasayama S, Iuchi K, Kameyama T. Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure. J Am Coll Cardiol 1987; 865-71.
4. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Eng J Med 1993; 329: 149-55.
5. Endoh M, Yanagisawa T, Taira N, Blinks JR. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Circulation 1986; 73 (suppl III): 111-17.
6. Iijima T, Taira N. Membrane current changes responsible for the positive inotropic effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of the guinea pig heart. J Pharmacol Exp Ther 1986; 240: 657-62.
7. Kitakaze M, Minamino T, Funaya H, et al. Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart. Circulation 1997; 95: 2108-14.
8. Shioi T, Matsumori A, Matsui S, Sasayama S. Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line. Life Sci 1993; 54: 11-6.
9. Maruyama I, Maruyama Y, Nakajima T, et al. Vesnarinone inhibits production of HIV-I in cultured cells. Biochem Biophys Res Commun 1993; 195: 1264-71.
10. y antigen expression by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1h)-quinolinone (vesnarinone) in a human salivary cancer cell line. Acta Histochem Cytochem 1994; 27: 591-9.
11. Nio Y, Ohmori H, Minari Y, et al. A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines. Anti-Cancer Drugs 1997; 8: 686-95.
12. Sato S, Tomoyasu S, Okabe-Kado J, et al. Induction of differentiation and enhancement of vincristine sensitivity of human erythroleukemia HEL cells by vesnarinone, a positive inotropic agent. Exp Hematol 1996; 24: 37-42.
13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
14. Kano Y, Ohnuma T, Okano T, Holland JF. Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 1988; 48: 351-6.
15. Kano Y, Suzuki K, Miyuki A, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 1992; 50: 604-10.
16. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-9.
17. Allen TE, Aliano NA, Cowan RJ, et al. Amplification of the antitumor activity of pleomycins and bleomycins in rats and mice by caffeine. Cancer Res 1985; 45: 2516-21.
18. Fingert HJ, Chang JD, Pardce AB. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res 1986; 46: 2463-7.
19. Fingert HJ, Pu AT, Chen Z, et al. In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. Cancer Res 1988; 48: 4375-81.
20. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein with multidrug resistance in mammalian cell lines. Science 1983; 23: 1285-7.
21. T 170 000 to 180 000 membrance glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res 1988; 48: 4926-32.
22. Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 1988; 85: 3580-4.
23. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine verapamil. Cancer Res 1981; 41: 1967-72.
24. Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 1989; 49: 5002-6.
25. Slater IM, Sweet P, Stupecky M, Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 1986; 77: 1405-8.
26. Sato W, Fukazawa N, Suzuki T, Yusa K, Tsuruo T. Circumvention of multidrug resistance by a newly synthesized quinoline derivative, MS-073. Cancer Res 1991; 51: 2420-4.
27. Sato W, Fukazawa N, Nakanishi O, et al. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 1995; 35: 271-7.
28. Baba M, Nakanishi O, Sato W, et al. Relationship between multidrug resistant gene expression and multidrug resistant-reversing effect of MS-209 in various tumor cells. Cancer Chemother Pharmacol 1995; 36: 361-7.
29. Sato M, Harada K, Yura Y, et al. The treatment with differentiation- and apoptosis-inducing agent, vesnarinone, of a patient with oral squamous cell carcinoma. Apoptosis 1997; 2: 313-8.
30. Kumakura T, Takase K, Terada N, Gelfand EW. Vesnarinone inhibits nucleoside and nucleobase transport. Life Sci 1995; 57: 75-81.
31. Shimabuku A, Nishida T, Ueda K, et al. Effects of vesnarinone on P-glycoprotein mediated multidrug resistance. Proc Am Cancer Res 1994; 35: 348 (abstr).